Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Vaibhav SahaiMichael RothePam K MangatElizabeth Garrett-MayerVijay SuhagElie G DibInderjit MehmiKunal C KadakiaEvan PisickHerbert L DuvivierPhat H LeRui LiDavid P MichelinRyan E WilcoxGina N GranthamDominique C HinshawAbigail GregorySusan HalabiRichard L SchilskyPublished in: JCO precision oncology (2024)
alterations.